Farrow Jeffrey S's Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 20, 2025
- Accession no.
- 0001819790-25-000054
- Filed
- Mar 20, 2025
- Trade date
- Mar 18-20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $178.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farrow Jeffrey SCIK 0001405253 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | Common Stock | SSaleDisposed | −1,284 | $46.29 | −$59,436.36 | 24,871 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −1,254 | $47.40 | −$59,439.6 | 23,617 | Direct | |
| Mar 20, 2025 | Common Stock | SSaleDisposed | −1,186 | $50.11 | −$59,430.46 | 22,431 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Chief Financial Officer and Chief Strategy Officer